Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Peter V who wrote (3524)	6/24/1998 9:05:00 PM
From: Quad Sevens	Read Replies (3) \| Respond to of 5736

<< And you've pissed me off. >> I'd be pissed off too if I wrote what you did and someone pointed out the glaring deficiencies. Now you're descending to namecalling. I can see I've wasted my time. Your neverending spiral of twisted contorted illogic will just have to go on without me. I stand by what I wrote. People reading it can decide on their own (if anyone is interested--probably not). Adios, Peter. Wade

To: Peter V who wrote (3524)	6/25/1998 8:20:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 5736

rockefeller.edu "Even in developed nations such as the United States, SnMP could provide a simple, inexpensive and more desirable therapy. Of the roughly 4 million births in the United States each year, about 75 percent or two and a half million infants develop visible jaundice. In about 10 percent of these infants, jaundice becomes severe enough to warrant treatment with light to prevent potential damage to the central nervous system." At least, from a source away from the CCSI/Asensio dyad. The 10% of treated babies is probably lower now with the recent recommendations from the American Academy of Pediatrics on Hyperbilirubinemia in Healthy Newborns, they recommend less treatment (and less testing) in infants in whom hemolytic disease is not suspected and are healthy (which are the majority of the jaundice babies.) In my opinion, CCSI should have no problem with the billing codes, if they are able to show to insurance companies the correspondent and "substantial" savings when comparing to the heel stick blood sample, which I do not consider difficult for CCSI to do. statcan.ca last one for the Canadian babies. Lets calculate the market size.